丙型肝炎治疗药物研究与设计

《丙型肝炎治疗药物研究与设计》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、目录丙型肝炎治疗药物研究与设计………………………………………………………3以生命周期划分HCV治疗药物整理………………………………………4HCV的结构………………...……………………………………………4HCV生命周期………………………………………………………...…5以生命周期划分HCV治疗药物整理…………………………..............6总结和展望………………………...…………………………..……….13基于NS5A抑制剂的创新药物设计………………………………………14前言................

2、..........................................................................................14NS5A靶点...............................................................................................14NS5A抑制剂研究进展........................................................

3、...................15BMS-790052(daclatasvir)研究................................................................20创新药物设计..........................................................................................24参考文献................................................

4、..................................................26TLR-7激动剂研究与设计………………………………………………….29目前已开发的激动剂..............................................................................29咪唑喹啉胺（imidazoquinolineamine）类..................................291-取代吡唑啉酮（1-Substitute

5、dPyrazolo(3,4-C)Ring）类......318-氧-去氮嘌呤类/咪唑并吡啶酮类............................................328-羟基腺嘌呤（8-Hydroxyadenine）类......................................36扩环8-羟基腺嘌呤类..................................................................57艾沙托立宾（Isatoribine）衍生物类...

6、.......................................61BitriazolylAcyclonucleoside类...................................................64三氮唑类（Triazole）.................................................................65嘧啶类（Pyrimidine）............................................

7、.....................668-SubstituedBenzoazepines类....................................................68Aminodiazepine类.......................................................................69未来可能的变动空间..............................................................

8、................70创新药物设计..........................................................................................71参考文献..............................................